Rare Genetic Variations Linked to Schizophrenia
|
By LabMedica International staff writers Posted on 09 Dec 2016 |

Image: Chromosome ideograms showing some locations of genome-wide significant linkages in schizophrenia and bipolar disorder. Asterisks mark the locations of chromosomal abnormalities associated with schizophrenia (Photo courtesy of SPL).
Genetic variations that increase schizophrenia risk are rare, making it difficult to study their role and to overcome this. Recently, the genomes of more than 41,000 people have been analyzed in the largest study of its kind to date.
The mutations, known as copy number variants, are deletions or duplications of the DNA sequence. A copy number variant (CNC) may affect dozens of genes, or it can disrupt or duplicate a single gene. This type of variation can cause significant alterations to the genome and lead to psychiatric disorders.
A large team of international scientists led by those at the University of California, San Diego School of Medicine (La Jolla, CA, USA) analyzed the genomes of 21,094 people with schizophrenia and 20,227 people without schizophrenia. They found eight locations in the genome with copy number variants associated with schizophrenia risk. Only a small fraction of cases (1.4%) carried these variants. The team also found that these copy number variants occurred more frequently in genes involved in the function of synapses, the connections between brain cells that transmit chemical messages.
Genome-wide significant evidence was obtained for eight loci, including 1q21.1, 2p16.3 (NRXN1), 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2 and 22q11.2. Suggestive support was found for eight additional candidate susceptibility and protective loci, which consisted predominantly of CNVs mediated by non-allelic homologous recombination. With its large sample size, this study had the power to find copy number variants with large effects that occur in more than 0.1%of schizophrenia cases. However, the team said they are still missing many variants. More analyses will be needed to detect risk variants with smaller effects, or ultra-rare variants.
Jonathan Sebat, PhD, a Professor of Psychiatry and Cellular and Molecular Medicine and the lead investigator of the study said, “This study represents a milestone that demonstrates what large collaborations in psychiatric genetics can accomplish. We are confident that applying this same approach to a lot of new data will help us discover additional genomic variations and identify specific genes that play a role in schizophrenia and other psychiatric conditions.” The study was published on November 21, 2016, in the journal Nature Genetics.
Related Links:
University of California, San Diego School of Medicine
The mutations, known as copy number variants, are deletions or duplications of the DNA sequence. A copy number variant (CNC) may affect dozens of genes, or it can disrupt or duplicate a single gene. This type of variation can cause significant alterations to the genome and lead to psychiatric disorders.
A large team of international scientists led by those at the University of California, San Diego School of Medicine (La Jolla, CA, USA) analyzed the genomes of 21,094 people with schizophrenia and 20,227 people without schizophrenia. They found eight locations in the genome with copy number variants associated with schizophrenia risk. Only a small fraction of cases (1.4%) carried these variants. The team also found that these copy number variants occurred more frequently in genes involved in the function of synapses, the connections between brain cells that transmit chemical messages.
Genome-wide significant evidence was obtained for eight loci, including 1q21.1, 2p16.3 (NRXN1), 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2 and 22q11.2. Suggestive support was found for eight additional candidate susceptibility and protective loci, which consisted predominantly of CNVs mediated by non-allelic homologous recombination. With its large sample size, this study had the power to find copy number variants with large effects that occur in more than 0.1%of schizophrenia cases. However, the team said they are still missing many variants. More analyses will be needed to detect risk variants with smaller effects, or ultra-rare variants.
Jonathan Sebat, PhD, a Professor of Psychiatry and Cellular and Molecular Medicine and the lead investigator of the study said, “This study represents a milestone that demonstrates what large collaborations in psychiatric genetics can accomplish. We are confident that applying this same approach to a lot of new data will help us discover additional genomic variations and identify specific genes that play a role in schizophrenia and other psychiatric conditions.” The study was published on November 21, 2016, in the journal Nature Genetics.
Related Links:
University of California, San Diego School of Medicine
Latest Molecular Diagnostics News
- Urine Test Detects Inherited Neuropathy Missed by Genetic Screening
- Genomic Test Predicts Risk of SCC Metastasis
- Microfluidic Device Predicts Pancreatic Cancer Recurrence After Surgery
- New Molecular Test Simultaneously Detects Three Major Fungal Infections
- Blood Test Guides More Effective Ovarian Cancer Treatment
- Liquid Biopsy Test to Enable Earlier Diagnosis of Numerous Cancer Types
- Blood Protein Profile Indicates Early-Onset Coronary Heart Disease
- New DNA Test Tracks Spread of Parasitic Disease from Single Sample
- Hidden Blood Biomarkers to Revolutionize Diagnosis of Diabetic Kidney Disease
- Genetic Testing Trifecta Predicts Risk of Sudden Cardiac Death and Arrhythmia
- Maternal Blood Test Detects Pre-Eclampsia Risk Before Symptoms Develop
- Blood Test Could Assess Concussion Severity in Teenagers with TBI
- Simultaneous Analysis of Three Biomarker Tests Detects Elevated Heart Disease Risk Earlier
- New Biomarker Panel to Improve Heart Failure Diagnosis in Women
- Dual Blood Biomarkers Improve ALS Diagnostic Accuracy
- Automated Test Distinguishes Dengue from Acute Fever-Causing Illnesses In 18 Minutes
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read moreMicrobiology
view channel
Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. Despite TB infecting 10 million people yearly, the... Read more
15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
Distinguishing minor childhood illnesses from potentially life-threatening infections such as sepsis or meningitis remains a major challenge in emergency care. Traditional tests can take hours, leaving... Read more
High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read morePathology
view channel
Blood Test and Sputum Analysis Predict Acute COPD Exacerbation
Chronic obstructive pulmonary disease (COPD) remains a major contributor to global illness, largely driven by cigarette smoking and marked by irreversible lung damage. Acute exacerbations can accelerate... Read more
AI Tool to Transform Skin Cancer Detection with Near-Perfect Accuracy
Melanoma continues to be one of the most difficult skin cancers to diagnose because it often resembles harmless moles or benign lesions. Traditional AI tools depend heavily on dermoscopic images alone,... Read more
Unique Immune Signatures Distinguish Rare Autoimmune Condition from Multiple Sclerosis
Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) is a rare autoimmune disorder in which the immune system attacks the myelin sheath in the central nervous system. Although symptoms... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








